HIGHLIGHTS
- who: Li Liu et al. from the Department of Radiology, University of Texas Southwestern Medical Center, Dallas, TX, USA have published the Article: Demonstrating Tumor Vascular Disrupting Activity of the Small-Molecule Dihydronaphthalene Tubulin-Binding Agent OXi6196 as a Potential Therapeutic for Cancer Treatment, in the Journal: (JOURNAL)
- what: We have for the first time demonstrated dose dependent vascular shutdown caused by OXi6197 in RENCA kidney tumors growing orthotopically in mice.
- future: As with other VDAs OXi6197 failed to fully control tumor growth but the promising preliminary therapeutic results suggest opportunities for future . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.